• Explore /
  • Poster
  • / Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.

Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.

Abstract Video & Slides Poster

Authors

null

Manish Sharma

START-Midwest, Grand Rapids, MI

Manish Sharma , Richard D. Carvajal , Glenn J. Hanna , Bob T. Li , Kathleen N. Moore , Mark D. Pegram , Drew W. Rasco , Alexander I. Spira , Michael Alonso , Liang Fang , Amreen Husain , Edith A. Perez , Ecaterina Elena Dumbrava

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04278144

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2549)

DOI

10.1200/JCO.2021.39.15_suppl.2549

Abstract #

2549

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Bob T. Li

First Author: Timothy Jay Price

First Author: Ozgur Karakuzu

First Author: Do-Youn Oh